Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax
TOKUSHIMA, Japan--(BUSINESS WIRE)--Apr 8, 2024--
Source: eagletribune.com
Fly Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Fly Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Fly Pharma Today - Breaking & Trending Today
Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO ann
TOKUSHIMA, Japan--(BUSINESS WIRE)--Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status.A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Ange...
Source: pharmiweb.com
Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-1
TOKUSHIMA, Japan--(BUSINESS WIRE)--We are excited to share our latest development status.As presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib (20 mg/day) in stage III/IV non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation positive in a...
Source: pharmiweb.com
Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323
TOKUSHIMA, Japan — We are excited to share our latest development status.
Source: financialpost.com
Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-10917
Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the treatment of Acute Myeloid
Source: finanznachrichten.de